Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Phase 4
500
about 7.5 years
6–17
4 sites in FL, NY, OH +1
About this study
This trial is testing how genetic variations in carboxylesterase 1 (CES1) affect the way methylphenidate (MPH), a medication, works in children with ADHD. The goal is to find out if certain CES1 genes are linked to how MPH affects people with ADHD.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Methylphenidate
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
methylphenidate (CNS stimulant; blocks reuptake of dopamine and norepinephrine)
oral (Disintegrating Oral Tablet)
Primary: Maximum methylphenidate plasma concentration (Cmax),
Secondary: Time to maximum concentration (Tmax)
Psychiatry / Mental Health